144 related articles for article (PubMed ID: 23208052)
21. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment.
Leone M; Priester MI; Romeijn S; Nejadnik MR; Mönkäre J; O'Mahony C; Jiskoot W; Kersten G; Bouwstra JA
Eur J Pharm Biopharm; 2019 Jan; 134():49-59. PubMed ID: 30453025
[TBL] [Abstract][Full Text] [Related]
22. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
[TBL] [Abstract][Full Text] [Related]
23. Transdermal delivery of vaccines - Recent progress and critical issues.
Ita K
Biomed Pharmacother; 2016 Oct; 83():1080-1088. PubMed ID: 27544552
[TBL] [Abstract][Full Text] [Related]
24. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous vaccination: antigen delivery into or onto the skin.
Weniger BG; Glenn GM
Vaccine; 2013 Jul; 31(34):3389-91. PubMed ID: 23684830
[No Abstract] [Full Text] [Related]
26. Compositional optimization and safety assessment of a hydrogel patch as a transcutaneous immunization device.
Matsuo K; Ishii Y; Quan YS; Kamiyama F; Asada H; Mukai Y; Okada N; Nakagawa S
Biol Pharm Bull; 2011; 34(12):1835-40. PubMed ID: 22130239
[TBL] [Abstract][Full Text] [Related]
27. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
[TBL] [Abstract][Full Text] [Related]
28. Characterization of transcutaneous protein delivery by a hydrogel patch in animal, human, and tissue-engineered skin models.
Matsuo K; Ishii Y; Quan YS; Kamiyama F; Mukai Y; Okada N; Nakagawa S
Biol Pharm Bull; 2011; 34(4):586-9. PubMed ID: 21467651
[TBL] [Abstract][Full Text] [Related]
29. Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines.
An M; Liu H
Small; 2017 Jul; 13(26):. PubMed ID: 28544329
[TBL] [Abstract][Full Text] [Related]
30. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
[TBL] [Abstract][Full Text] [Related]
31. Understanding the basis of transcutaneous vaccine delivery.
Gamazo C; Pastor Y; Larrañeta E; Berzosa M; Irache JM; Donnelly RF
Ther Deliv; 2019 Jan; 10(1):63-80. PubMed ID: 30730825
[TBL] [Abstract][Full Text] [Related]
32. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery.
Mönkäre J; Pontier M; van Kampen EEM; Du G; Leone M; Romeijn S; Nejadnik MR; O'Mahony C; Slütter B; Jiskoot W; Bouwstra JA
Eur J Pharm Biopharm; 2018 Aug; 129():111-121. PubMed ID: 29803720
[TBL] [Abstract][Full Text] [Related]
33. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
Denis F; Alain S; Ploy MC
Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
[TBL] [Abstract][Full Text] [Related]
34. [Development of a transcutaneous vaccination system using a hydrogel patch].
Ishii Y; Okada N; Nakagawa S
Nihon Rinsho; 2008 Oct; 66(10):1848-50. PubMed ID: 18939480
[No Abstract] [Full Text] [Related]
35. Vaccination with influenza hemagglutinin-loaded ceramic nanoporous microneedle arrays induces protective immune responses.
Schepens B; Vos PJ; Saelens X; van der Maaden K
Eur J Pharm Biopharm; 2019 Mar; 136():259-266. PubMed ID: 30731115
[TBL] [Abstract][Full Text] [Related]
36. The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains.
Wedlock PT; Mitgang EA; Elsheikh F; Leonard J; Bakal J; Welling J; Crawford J; Assy E; Magadzire BP; Bechtel R; DePasse JV; Siegmund SS; Brown ST; Lee BY
Vaccine; 2019 Jan; 37(4):645-651. PubMed ID: 30578088
[TBL] [Abstract][Full Text] [Related]
37. Long-term stability of influenza vaccine in a dissolving microneedle patch.
Mistilis MJ; Joyce JC; Esser ES; Skountzou I; Compans RW; Bommarius AS; Prausnitz MR
Drug Deliv Transl Res; 2017 Apr; 7(2):195-205. PubMed ID: 26926241
[TBL] [Abstract][Full Text] [Related]
38. Delivery of antigens used for vaccination: recent advances and challenges.
Scherliess R
Ther Deliv; 2011 Oct; 2(10):1351-68. PubMed ID: 22826888
[TBL] [Abstract][Full Text] [Related]
39. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
[TBL] [Abstract][Full Text] [Related]
40. Microneedle-mediated delivery of viral vectored vaccines.
Zaric M; Ibarzo Yus B; Kalcheva PP; Klavinskis LS
Expert Opin Drug Deliv; 2017 Oct; 14(10):1177-1187. PubMed ID: 27591122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
